Uses and Abuses of Antipyretic Therapy
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Antipyretic Efficacy of an Initial 30-Mg/Kg Loading Dose of Acetaminophen Versus a 15-Mg/Kg Maintenance Dose
Antipyretic Efficacy of an Initial 30-mg/kg Loading Dose of Acetaminophen Versus a 15-mg/kg Maintenance Dose Jean Marc Tre´luyer, MD, PhD*; Sylvie Tonnelier, PharmD*; Philippe d’Athis‡; Beatrice Leclerc§; Isabelle Jolivet-Landreau, MD§; and Ge´rard Pons, MD, PhD* ABSTRACT. Objective. To compare the antipyretic comfort.1 Among the available antipyretic agents, efficacy of an initial 30-mg/kg acetaminophen loading acetaminophen is one of the most widely used be- dose versus a 15-mg/kg maintenance dose. cause it has an antipyretic efficacy equivalent to the Methods. A double-blind, parallel-group, random- other antipyretic drugs and a good safety profile.2–4 ized clinical trial was conducted. A total of 121 febrile Acetaminophen antipyretic efficacy is dose-depen- (rectal temperature between 39°C and 40°C) but other- dent.5,6 The recommended dose is 15 mg/kg every 6 wise healthy outpatients who were 4 months to 9 years of 2 age and weighed 4 to 26 kg were assigned randomly to 1 hours. Following this dosing schedule, it usually -takes several hours after the first acetaminophen ad ؍ and 30 mg/kg (n (62 ؍ of the dose groups: 15 mg/kg (n 59). ministration to obtain the maximal clinical efficacy of Results. In an “intention to treat” analysis, the time to the drug.7 Therefore, Mahar et al8 suggested a phys- obtain a temperature lower than 38.5°C was significantly ical “cold therapy” at the initiation of the chemical shorter in the 30-mg/kg than in the 15-mg/kg group treatment to decrease the time course to antipyretic minutes vs 139 ؎ 113 minutes). -
Clinical Report—Fever and Antipyretic Use in Children Abstract
Guidance for the Clinician in Rendering Pediatric Care Clinical Report—Fever and Antipyretic Use in Children Janice E. Sullivan, MD, Henry C. Farrar, MD, and the abstract SECTION ON CLINICAL PHARMACOLOGY AND THERAPEUTICS, and COMMITTEE ON DRUGS Fever in a child is one of the most common clinical symptoms managed by pediatricians and other health care providers and a frequent cause KEY WORDS fever, antipyretics, children of parental concern. Many parents administer antipyretics even when ABBREVIATIONS there is minimal or no fever, because they are concerned that the child NSAID—nonsteroidal anti-inflammatory drug must maintain a “normal” temperature. Fever, however, is not the The guidance in this report does not indicate an exclusive primary illness but is a physiologic mechanism that has beneficial course of treatment or serve as a standard of medical care. effects in fighting infection. There is no evidence that fever itself wors- Variations, taking into account individual circumstances, may be ens the course of an illness or that it causes long-term neurologic appropriate. complications. Thus, the primary goal of treating the febrile child This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors should be to improve the child’s overall comfort rather than focus on have filed conflict of interest statements with the American the normalization of body temperature. When counseling the parents Academy of Pediatrics. Any conflicts have been resolved through or caregivers of a febrile child, the general well-being of the child, the a process approved by the Board of Directors. -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Pharmacological Evaluation of Novel Dimers of an Arylpropionic Acid Class of Non-Selective Cyclooxygenase Inhibitors
Halimi et al Tropical Journal of Pharmaceutical Research February 2017; 16 (2): 327-336 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v16i2.10 Original Research Article Pharmacological evaluation of novel dimers of an arylpropionic acid class of non-selective cyclooxygenase inhibitors Syed Muhammad Ashhad Halimi1*, Muhammad Saeed1, Safiullah1 and Khalid Muhammed Khan2 1Department of Pharmacy, University of Peshawar, Peshawar 25120, 2H.E.J. International Centre for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi 75270, Pakistan *For correspondence: Email: [email protected]; Tel: +92 91 9216750; Fax: +92 91 9218318 Received: 4 August 2016 Revised accepted: 5 January 2017 Abstract Purpose: To explore and identify cyclooxygenase (COX) inhibitors with optimal potency and efficacy using an arylpropionic acid class of drugs as lead molecules. Methods: The selected lead molecules were dimerised through chemical processes (reflux condensation) and characterised in terms of structural properties using infrared, proton nuclear magnetic resonance, electron impact mass spectrometry, and elemental analysis techniques. The molecules were evaluated pharmacologically for acute toxicity and anti-inflammatory (carrageenan- induced paw oedema test), analgesic (acetic acid-induced writhing test in mice), and antipyretic (Brewer’s yeast-induced pyrexia test in mice) activities against control (normal saline) and relevant reference standard drugs. Docking analyses were also performed to assess possible protein–ligand interactions. Results: The test compounds were non-toxic at doses of 50, 100 and 150 mg/kg body weight, ip. -
Different Techniques for Analysis of Aspirin, Caffeine, Diclofenac Sodium and Paracetamol: Review Article
ISSN 2692-4374 Pharmaceutical Sciences | Review Article Different techniques for Analysis of Aspirin, Caffeine, Diclofenac Sodium and Paracetamol: Review Article Mahmoud M. Sebaiy1*, Sobhy M. El-Adl1, and Amr A. Mattar1&2 1 Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt. 2 Pharmaceutical Medicinal Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt. *Аuthоrcоrrеspоndеncе: Е-mаil: mmsеbаiу@zu.еdu.еg; sеbаiуm@gmаil.cоm.Tеl: 01062780060. Fаx: 0552303266 Submitted: 27 April 2020 Approved: 11 May 2020 Published: 14 May 2020 How to cite this article: Sebaiy MM, El-Adl SM, Mattar AA. Different techniques for Analysis of Aspirin, Caffeine, Diclofenac Sodium and Paracetamol: Review Article. G Med Sci. 2020; 1(1): 013-031. https://www.doi.org/10.46766/thegms.pharma.20042701 Copyright: © 2020 Mahmoud MS. This is an open access article distributed under the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTracT Early treatment of pain is of a great importance as unrelieved pain can have profound psychological effects on the patient, and acute pain that is poorly managed initially can degenerate into chronic pain, which may prove to be much more difficult to treat. It is important to assess and treat the article,mental weand will emotional shed the aspects light on of different the pain waysas well of assome its physicalanalgesic aspects. drugs monitoring Although drug and therapyanalysis isusing a mainstay different of techniques pain treatment, in addition physical to methodsthe most such as physiotherapy (including massage and the application of heat and cold), surgery, and drug monitoring are also very valuable. -
Formulations Comprising Nanoparticulate Meloxicam
(19) TZZ¥ZZ¥__T (11) EP 3 090 731 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.11.2016 Bulletin 2016/45 A61K 9/14 (2006.01) A61K 31/5415 (2006.01) (21) Application number: 16161176.9 (22) Date of filing: 27.02.2004 (84) Designated Contracting States: • Ryde, Tuula AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Malvern, PA Pennsylvania 19355 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • Pruitt, John, D. Suwanee, GA Georgia 30024 (US) (30) Priority: 03.03.2003 US 450705 P • Kline, Laura Harleysville, PA Pennsylvania 19438 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Wichmann, Hendrik 08006465.2 / 1 938 803 Wuesthoff & Wuesthoff 04785761.0 / 1 617 816 Patentanwälte PartG mbB Schweigerstraße 2 (71) Applicant: DV Technology LLC 81541 München (DE) Wilmington, Delaware 19801 (US) Remarks: (72) Inventors: This application was filed on 18-03-2016 as a • Cooper, Eugene, R. divisional application to the application mentioned Berwyn, PA Pennsylvania 19312 (US) under INID code 62. (54) FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM (57) The present invention is directed to composi- than about 2 microns; wherein said effective average par- tions comprising meloxicam. The stable meloxicam com- ticle size is different than the particle size of the nano- positions comprise (a) nanoparticulate particles of mel- particulate particles of meloxicam (a); and (c) at least one oxicam having an effective average particle size of less surface stabilizer. The invention relates also to uses of than about 2000 nm, (b) particles of meloxicam having the composition. -
Non Steroidal Anti-Inflammatory Drugs
Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney. -
Emit®Tox™ Salicylic Acid Assay
3 METHODOLOGY The Emit® tox™ Salicylic Acid Assay is a homogeneous enzyme immunoassay technique used for the quantitative analysis of salicylic acid in human serum or plasma.7 In the performance of the Emit® tox™ Salicylic Acid Assay, serum or plasma is mixed with Reagent 1, which contains antibodies to salicylic acid and the coenzyme nicotinamide adenine dinucleotide (NAD). Subsequently, Reagent 2, which contains salicylic acid ™ labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH), is added. Salicylic acid in Emit tox Salicylic Acid Assay the sample and salicylic acid-labeled G6PDH compete for antibody binding sites. Enzyme activity ® decreases upon binding to the antibody, so the salicylic acid concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized NAD to NADH, resulting May 2012 7S052.2D_C in an absorbance change that is measured spectrophotometrically. Endogenous G6PDH does not interfere because the coenzyme functions only with the bacterial (Leuconostoc mesenteroides) enzyme employed in the assay. See shaded sections: Updated information from August 2010 version. 4 REAGENTS Reagents contain the following substances: Mouse monoclonal antibodies reactive to salicylic acid (60.4 µg/mL),* salicylic acid labeled with bacterial G6PDH (0.34 U/mL), glucose-6-phosphate (22 mM), nicotinamide adenine dinucleotide (18 mM), Tris buffer, bovine serum albumin, preservatives, and stabilizers. Catalog Quantity/ *The antibody titer and enzyme conjugate activity may vary from lot to lot. Number Product Description Volume For in vitro diagnostic use. OSR7S229 Emit® tox™ Salicylic Acid Assay Precautions OSR7S518 R1 (Antibody/Substrate Reagent 1) 2 x 32 mL • Reagents contains nonsterile mouse monoclonal antibodies. -
09 Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
Part I Anaesthesia Refresher Course – 2017 09 University of Cape Town Non-steroidal anti-inflammatory drugs (NSAIDs) Dr Ernest Welch Private Practice Honorary lecturer- Wits University Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of unrelated chemical compounds that have analgesic, anti-inflammatory and antipyretic effects. The similarity in therapeutic actions and side effects is due to common mechanisms of action and as a result they can be studied as a single class of drugs. The understanding of the NSAIDs, their effects and controversies is dependent on knowledge of the COX (cyclo-oxygenase) enzyme system. Mechanism of action Basic physiology of the COX pathway: 1. Fatty acid metabolism results in the production of prostaglandins (PG) via the COX pathway. 2. PGs mediate: inflammation, pain, pyrexia, cell mitosis and neuromuscular function. 3. All NSAIDs inhibit cyclo-oxygenase (COX). Formation of prostaglandin Arachidonic acid (AA) is a phospholipid fatty acid found in cell membranes that is released by a variety of stimuli particularly membrane damage. Cyclo-oxygenase (COX) and lipoxygenase (LOX) enzymes convert Arachidonic acid (AA) to lipid mediator’s PG and leukotrienes (also known as the eicosanoids) The two COX isoforms (COX-1 and COX-2) catalyse AA to PG and thromboxane (TxA) Initially COX converts AA to prostaglandin G2 (PGG2), and then converts PGG2 to prostaglandin H2 (PGH2) PGH2 is converted to 5 active forms of PG prostaglandin D2 (PGD2), prostaglandin E2 (PGE2) prostaglandin F2α (PGF2α) prostacyclin (PGI2) thromboxane A2 (TxA2) These 5 prostanoids act as secondary messengers mainly on G protein-coupled receptors. THE SYNTHESIS OF PROSTOGLANDINS USING CYCLO-OXYGENASE S. -
Determination of Amtolmetin and Its Active Metabolites in Plasma by HPLC-UV: Application to a Bioequivalence Study Punnamchand Loya1 and Madhusudan N
Journal of Bioequivalence & Bioavailability - Open Access JBB/Vol.2 Issue 2 Research Article OPEN ACCESS Freely available online doi:10.4172/jbb.1000028 Determination of Amtolmetin and Its Active Metabolites in Plasma by HPLC-UV: Application to a Bioequivalence Study Punnamchand Loya1 and Madhusudan N. Saraf2* 1Ph.D (T) research scholar, The Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai-400 098 2Principal & Professor of Pharmacolgy, The Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai-400 098 Abstract Mancinelli et al. (1991) described a method for the determi- nation of amtolmetin and its metabolite from rats plasma. Al- A simple, rapid and selective method was developed for though the method is quite sensitive it requires a gradient HPLC the determination of amtolmetin guacil, tolmetin sodium and along with the liquid-liquid extraction which is time consum- tolmetin glycinamide from human plasma. The method in- ing and also the solvent used for extraction are well known car- volves extracting amtolmetin guacil, tolmetin sodium and cinogens, which may be difficult in handling as lot of samples tolmetin glycinamide with acetonitrile using coumarin as analysed for a bioequivalence study. Annunziato and di Renzo, internal standard. Chromatographic separation was carried (1993) described a method for the analysis of AG for a bioequivalence of two 600 mg AG capsules. (Only abstract is out on a C8 column using mixture of acetonitrile:methanol: available as the method literature is published in Italian lan- 1% acetic acid as mobile phase with UV detection set at guage). The other reported methods for determination of tolmetin 313 nm. The retention time of AG, T, TG and IS were (one of the active metabolite of amtolmetin) and its metabolites, 8.20±0.2, 5.3±0.2, 4.0±0.2 and 4.9±0.2 min, respectively. -
A Review of Toxicity from Topical Salicylic Acid Preparations
A review of toxicity from topical salicylic acid preparations RamanK.Madan,MD,a,b and Jacob Levitt, MDb New York, New York Topical salicylic acid is often used in dermatologic conditions because of its keratolytic, bacteriostatic, fungicidal, and photoprotective properties. The bioavailability of salicylic acid differs depending on the vehicle used and pH of transcellular fluids. Although rare, salicylic acid toxicity (salicylism) can occur from topical application. Physicians should be mindful of the potential for salicylism or even death from topically applied salicylic acid. ( J Am Acad Dermatol 2014;70:788-92.) Key words: ichthyosis; psoriasis; salicylic acid; salicylism; skin absorption; topical; toxicity. alicylic acid is the most widely consumed to 40%. Prescription-strength creams and lotions analgesic, antipyretic, and anti-inflammatory contain concentrations of 6% or above. S 1 agent in the world. It is a natural product The potency and toxicity of salicylic acid is found in the bark of a willow tree and has been used changed by substitutions on the carboxyl or for centuries to relieve fever and pain.2 Salicylic acid hydroxyl groups of its chemical structure. Its action is a precursor to acetylsalicylic acid, better known as is also influenced by the ortho position of the aspirin (Fig 1).3 hydroxyl group. This structure allows for the effects Salicylic acid is used topically for its keratolytic, of salicylic acid on pain, body temperature, respira- bacteriostatic, fungicidal, and photoprotective prop- tion, acid-base balance, kidneys, heart, gastrointes- erties. Topical application has been shown to reduce tinal tract, uric acid excretion, blood, and rheumatic, the rate of keratinocyte proliferation. -
Method and Use for Increasing Efficacy of Anti-Adhesive Compositions in Controlling Inflammation and Pain
(19) & (11) EP 2 465 513 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.06.2012 Bulletin 2012/25 A61K 31/77 (2006.01) A61K 33/06 (2006.01) A61K 45/06 (2006.01) A61P 29/00 (2006.01) (21) Application number: 11195175.2 (22) Date of filing: 12.11.2007 (84) Designated Contracting States: (72) Inventor: Chamness, Kathy L. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Memphis, TN 38104-5305 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: O’Connell, Maura et al FRKelly (30) Priority: 13.11.2006 US 598397 27 Clyde Road Ballsbridge (62) Document number(s) of the earlier application(s) in Dublin 4 (IE) accordance with Art. 76 EPC: 07864257.6 / 2 104 505 Remarks: •This application was filed on 22-12-2011 as a (71) Applicant: Warsaw Orthopedic, Inc. divisional application to the application mentioned Warsaw, IN 46581 (US) under INID code 62. •Claims filed after the date of filing of the application (Rule 68(4) EPC). (54) Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain (57) The invention discloses a method and kit thereof prising an effective amount of at least one pharmaceuti- for increasing the efficiency of anti-adhesive composi- cally-acceptable anti-adhesive non-ionic polymer to a tions by parenterally administering a composition com- site of injury, controlling inflammation at the site of injury, and reducing pain. EP 2 465 513 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 465 513 A2 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to methods of increasing efficacy of anti-adhesive compositions by parental administration of compositions containing anti-adhesive polymers and magnesium salts.